Updated hourlyHourly refreshSun, Oct 25, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance · Biotech & pharma
San Diego, California--(August 20, 2026) - Robbins Geller Rudman & Dowd LLP is investigating potential violations of United States federal securities laws involving Sionna Therapeutics, Inc. (NASDAQ: SION).If you have information that could assist in the Sionna Therapeutics investigation or if you are a Sionna Therapeutics investor who suffered a loss and would like to learn more, you can provide your information...
Aug 20 · 22:38·Newsfile
Finance · Biotech & pharma
SAN DIEGO, Aug. 20, 2026 -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on August 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the...
Aug 20 · 22:23·PR Newswire
Finance · Biotech & pharma
LOS ANGELES, Aug. 20, 2026 -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming September 28, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 inclusive (the “Class Period”).
Aug 20 · 21:15·GlobeNewswire
Healthcare · Biotech & pharma
First Alzheimer's blood test cleared for patients as young as 40, advancing the ADDF's long-standing push to close the gap between early pathology and early detection Milestone reflects nearly two decades of sustained ADDF investment, expanding access to scalable blood-based diagnostics...
Aug 20 · 21:01·PR Newswire
Biotech & pharma
TORONTO, and HAIFA, Israel, Aug. 21, 2026 -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that it has closed a non-brokered private placement of 1,938,326 units (“Units”) at a price of C$0.55 per Unit for aggregate gross proceeds of approximately C$1,066,078.02 (the “Offering”), subject to final acceptance of the TSX Venture Exchange (“TSXV”). The Company intends to use the proceeds of the Offering for general working capital purposes. No insiders participated in this Offering and no finder’s fees were paid in connection with this Offering.
Aug 20 · 21:01·GlobeNewswire
Biotech & pharma
Did you buy CAPR securities between December 17, 2025 and July 26, 2026?
Aug 20 · 18:03·GlobeNewswire
Healthcare · Biotech & pharma
IRVINE, Calif., August 20, 2026--Immunis, Inc., a clinical-stage biotechnology company developing off-the-shelf multi-active biologics for muscle health and healthy aging, today announced that its Chairman, Dr. Hans Keirstead, has been nominated as a panelist at SXSW 2027 in a conversation titled "Can We Get Better at Aging?: Hope, Hype, and Hard Science."
Aug 20 · 17:28·Business Wire
Biotech & pharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ARS Pharmaceuticals between March 9, 2026 and June 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]New York, New...
Aug 20 · 15:41·Newsfile
Healthcare · Food & drink
Small manufacturers and distributors in food, beverage, pharmaceutical and medical device industries can now trace any batch from receipt to customer, at a fraction of the cost of an enterprise ERP. TORONTO, Aug. 20, 2026 -- inFlow Inventory has launched lot number and expiry...
Aug 20 · 15:11·PR Newswire
Biotech & pharma
Capricor Therapeutics (CAPR) Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
Aug 20 · 15:05·GlobeNewswire
AI · Biotech & pharma
Earlier diagnosis and wider reimbursement are expanding access, led by biosimilars, oral JAK and IL-17 therapies. Asia-Pacific, telehealth and AI imaging offer key opportunities.
Earlier diagnosis and wider reimbursement are expanding access, led by biosimilars, oral JAK and IL-17 therapies. Asia-Pacific, telehealth and AI imaging offer key opportunities.
Aug 20 · 15:04·GlobeNewswire
Biotech & pharma
Government vaccination programs, zoonotic-risk awareness and herd growth are boosting demand, while advanced vaccine platforms and stronger cold chains offer key opportunities.
Government vaccination programs, zoonotic-risk awareness and herd growth are boosting demand, while advanced vaccine platforms and stronger cold chains offer key opportunities.
Aug 20 · 15:03·GlobeNewswire